Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to find out the maximum tolerated dose (MTD) of bortezomib
(VELCADE) in combination with pralatrexate in patients with previously treated multiple
myeloma, AL amyloid and Waldenstroem's macroglobulinemia.